Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, announced today that Bristol-Myers Squibb's ill-fated hypertension drug, Vanlev (omapatrilat), has minimal market opportunity even in the sole remaining patient population left open for development-the patients with severe or uncontrolled hypertension.

(Photo: )

"Our findings indicate that even before the FDA's rejection of Vanlev, physicians would have only prescribed the drug to 6% of newly diagnosed hypertension patients," said Alice von Loesecke, senior director of research for PhysicianForum. "Physicians would have been more willing, however, to prescribe Vanlev to patients with uncontrolled hypertension following third- line therapy. But, even this subpopulation offers minimal commercial opportunity for Bristol-Myers Squibb."

The report entitled Hypertension: New Dynamics in a Mature Market also found that although generic versions of the leading ACE inhibitors used to treat hypertension are becoming available, in the near term many physicians will continue to prescribe the branded products.

"Our primary research finds that the initial erosion of branded ACE inhibitors may occur at a slower pace than in some other recent high profile patent expirations such as Lilly's Prozac. Primary care physicians indicate that they will initially keep approximately 50% of patients on branded ACE inhibitors even when generic versions of these molecules are available," said Ms. von Loesecke. " However, whether physicians will continue this high level of branded use over time is highly questionable, given typical generic erosion patterns."

Hypertension: New Dynamics in Mature Market includes surveys of sixty- eight U.S.-based primary care physicians who are high prescribers of cardiovascular drugs about diagnosis, referral, and treatment patterns in the hypertension population to learn how they manage hypertension patients (with and without comorbidities) and how those management practices will change following the imminent launch of new generic ACE inhibitors and the possible future launch of Vanlev.

About PhysicianForum

PhysicianForum is a new primary research service from Decision Resources. The service offers access to high-volume-prescribing primary care physicians, specialists, and manage care representatives in the United States and Europe; analysis of events and responses to them; insight into prescribing patterns; and predictions for the pharmaceutical market based on the results.

About Decision Resources

Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The Company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:    Elizabeth Marshall    Decision Resources    781-296-2563 


Photo: NewsCom:

AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563, or

Anti-Angiogenic Agents Hold Significant Potential for the Treatment of Cancer Propelling Them to Between $1 Billion and $3 Billion in Sales by 2011

View Now